Afferent Pharmaceuticals, Inc. clinical trials
Acquired by Merck & Co., Inc, Jul 26, 2016 · source ↗
The registry lists 15 studies whose lead sponsor is Afferent Pharmaceuticals, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 22, 2022.
- 15studies on the registry
- 0open to participants now
Before and after it joined Merck & Co., Inc
- First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- 15
- First submitted after Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Afferent Pharmaceuticals, Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 14
All 15 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 11
- 12
- 13
- 14
- 915
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)15 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 15 of 15. All Merck & Co., Inc studies →
- A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) FormulationsCompletedNCT02492776Phase 1
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)CompletedNCT02229877Phase 1
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)CompletedNCT02502097Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)CompletedNCT02397460Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009)CompletedNCT01993329Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)CompletedNCT01432730Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)CompletedNCT02349425Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)TerminatedNCT01569438Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)CompletedNCT02612610Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- An 8-Week Refractory Chronic Cough Study (MK-7264-021)CompletedNCT02612623Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the KneeCompletedNCT01554579Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02477709Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)CompletedNCT02476890Phase 2
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) FormulationsCompletedNCT02790840Phase 1
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc
- A Pharmacokinetics Study of AF-130 in Healthy SubjectsCompletedNCT02652936Phase 1
Sponsor listed in the registry: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Afferent Pharmaceuticals, Inc. became part of Merck & Co., Inc